Agena Bioscience Eyes New Year Target For Mass Spec Liquid Biopsy Launch

Agena Bioscience will launch two diagnostic panels for targeted testing of lung and colon cancer in Europe in January. The liquid biopsy technology is based on its benchtop mass spectrometer, the MassArray Dx Analyzer 4.

PCR strip test tubes and micropipette in genetics laboratory. Toned photo
Agena Bioscience set to launch two targeted diagnostic tests for lung and colon cancer • Source: Shutterstock

Agena Bioscience is ready to make its mark on the liquid biopsy landscape with two new lung and colon cancer test panels. The CE-IVD marked panels incorporate Agena's UltraSEEK chemistry for mutation detection and are intended for use on its MALDI-TOF-based MassArray Dx Analyzer 4 platform, which is currently sold in Europe, the US and the Asia-Pacific region. ([A#MT103965/])

The MassArray Dx Lung Panel and MassARRAY Dx Colon Panel have been used in pre-release for certain customers in the...

More from Oncology

More from Device Area